Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease

Nephrol Dial Transplant. 2009 Apr;24(4):1082-8. doi: 10.1093/ndt/gfn601. Epub 2008 Nov 5.

Authors

Nosratola D Vaziri¹, Xin J Zhou

Affiliation

¹ Division of Nephrology and Hypertension, UCI Medical Center, 101 The City Drive, Bldg 53 Rm 125 Rt 81, Orange, CA 92868, USA. ndvaziri@uci.edu

PMID: 18987263
DOI: 10.1093/ndt/gfn601

No abstract available

MeSH terms

Anemia / drug therapy*
Anemia / etiology
Anemia / physiopathology
Cardiovascular Diseases / complications
Chronic Disease
Erythropoietin / adverse effects
Erythropoietin / pharmacology
Erythropoietin / therapeutic use*
Hematinics / adverse effects
Hematinics / pharmacology
Hematinics / therapeutic use*
Humans
Kidney Diseases / complications*

Substances

Hematinics
Erythropoietin